| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Diseases | 5 | 2024 | 176 | 1.830 |
Why?
|
| Cosmeceuticals | 2 | 2025 | 2 | 1.770 |
Why?
|
| Skin | 9 | 2022 | 592 | 1.610 |
Why?
|
| Dermatology | 5 | 2025 | 46 | 1.460 |
Why?
|
| Hypopigmentation | 2 | 2022 | 6 | 1.440 |
Why?
|
| Child | 26 | 2025 | 7699 | 1.260 |
Why?
|
| Depression, Postpartum | 3 | 2025 | 17 | 1.220 |
Why?
|
| Postpartum Period | 3 | 2025 | 169 | 1.180 |
Why?
|
| Pediatrics | 2 | 2025 | 421 | 1.100 |
Why?
|
| Acne Vulgaris | 2 | 2017 | 34 | 0.980 |
Why?
|
| Infant | 13 | 2025 | 3332 | 0.940 |
Why?
|
| Humans | 72 | 2026 | 98135 | 0.890 |
Why?
|
| Vitiligo | 2 | 2022 | 20 | 0.880 |
Why?
|
| Mothers | 3 | 2025 | 146 | 0.870 |
Why?
|
| Feeding Behavior | 2 | 2025 | 350 | 0.870 |
Why?
|
| Exanthema | 2 | 2023 | 43 | 0.860 |
Why?
|
| Skin Diseases, Vesiculobullous | 4 | 2015 | 17 | 0.860 |
Why?
|
| Hair | 2 | 2018 | 56 | 0.850 |
Why?
|
| Maternal Behavior | 1 | 2025 | 56 | 0.850 |
Why?
|
| Malassezia | 1 | 2024 | 2 | 0.840 |
Why?
|
| Dermatomycoses | 1 | 2024 | 10 | 0.840 |
Why?
|
| Dermatologic Agents | 2 | 2025 | 79 | 0.840 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2023 | 5 | 0.790 |
Why?
|
| Food Addiction | 1 | 2023 | 1 | 0.790 |
Why?
|
| Dermatitis | 1 | 2023 | 34 | 0.770 |
Why?
|
| Infant, Newborn | 12 | 2026 | 2531 | 0.760 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2023 | 15 | 0.760 |
Why?
|
| Autoimmune Diseases | 2 | 2023 | 259 | 0.740 |
Why?
|
| Granuloma Annulare | 1 | 2022 | 3 | 0.720 |
Why?
|
| Vaccines | 2 | 2014 | 86 | 0.710 |
Why?
|
| Herpes Zoster | 1 | 2022 | 26 | 0.710 |
Why?
|
| Spider Bites | 1 | 2021 | 2 | 0.710 |
Why?
|
| Internship and Residency | 2 | 2021 | 1123 | 0.700 |
Why?
|
| Lichen Nitidus | 1 | 2021 | 1 | 0.690 |
Why?
|
| Papilloma | 1 | 2021 | 23 | 0.690 |
Why?
|
| Fingers | 1 | 2021 | 53 | 0.690 |
Why?
|
| Emotions | 1 | 2025 | 387 | 0.670 |
Why?
|
| Panniculitis | 2 | 2011 | 11 | 0.650 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 244 | 0.650 |
Why?
|
| Abnormalities, Multiple | 6 | 2022 | 235 | 0.650 |
Why?
|
| Skin Pigmentation | 2 | 2019 | 37 | 0.620 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 379 | 0.620 |
Why?
|
| Siblings | 2 | 2019 | 113 | 0.600 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2019 | 4 | 0.600 |
Why?
|
| Trichothiodystrophy Syndromes | 1 | 2019 | 4 | 0.600 |
Why?
|
| Calcineurin Inhibitors | 2 | 2018 | 55 | 0.600 |
Why?
|
| Child, Preschool | 11 | 2024 | 4006 | 0.570 |
Why?
|
| Dermatitis, Atopic | 3 | 2016 | 71 | 0.560 |
Why?
|
| Alopecia Areata | 1 | 2018 | 5 | 0.550 |
Why?
|
| Hydroxychloroquine | 1 | 2018 | 15 | 0.550 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 24 | 0.530 |
Why?
|
| Adolescent | 14 | 2025 | 10097 | 0.530 |
Why?
|
| Female | 36 | 2026 | 51570 | 0.530 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 638 | 0.520 |
Why?
|
| Molluscum Contagiosum | 1 | 2017 | 1 | 0.520 |
Why?
|
| Hypersensitivity | 1 | 2019 | 166 | 0.520 |
Why?
|
| Vascular Malformations | 2 | 2016 | 19 | 0.490 |
Why?
|
| Skin Diseases, Vascular | 1 | 2016 | 5 | 0.480 |
Why?
|
| Lymphatic Diseases | 1 | 2016 | 31 | 0.480 |
Why?
|
| Pandemics | 2 | 2022 | 916 | 0.480 |
Why?
|
| Ice | 1 | 2015 | 11 | 0.470 |
Why?
|
| Frostbite | 1 | 2015 | 9 | 0.460 |
Why?
|
| Cryotherapy | 1 | 2015 | 31 | 0.460 |
Why?
|
| Insect Bites and Stings | 1 | 2015 | 2 | 0.460 |
Why?
|
| Knee Injuries | 1 | 2015 | 57 | 0.450 |
Why?
|
| Male | 29 | 2025 | 47109 | 0.440 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 642 | 0.440 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 811 | 0.430 |
Why?
|
| Arthroscopy | 1 | 2015 | 110 | 0.430 |
Why?
|
| Miliaria | 2 | 2024 | 2 | 0.430 |
Why?
|
| Drug Eruptions | 1 | 2014 | 35 | 0.420 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 303 | 0.410 |
Why?
|
| Mutation | 6 | 2019 | 4392 | 0.410 |
Why?
|
| Limb Deformities, Congenital | 2 | 2016 | 17 | 0.400 |
Why?
|
| Intimate Partner Violence | 2 | 2025 | 36 | 0.400 |
Why?
|
| Diagnosis, Differential | 7 | 2024 | 1568 | 0.390 |
Why?
|
| Leg Dermatoses | 1 | 2013 | 7 | 0.380 |
Why?
|
| Acrodermatitis | 1 | 2013 | 4 | 0.380 |
Why?
|
| Mental Health | 2 | 2025 | 219 | 0.380 |
Why?
|
| Facial Dermatoses | 1 | 2013 | 16 | 0.380 |
Why?
|
| Netherton Syndrome | 1 | 2012 | 2 | 0.370 |
Why?
|
| Ultraviolet Therapy | 1 | 2012 | 17 | 0.370 |
Why?
|
| HIV Infections | 1 | 2022 | 1018 | 0.360 |
Why?
|
| Mammography | 3 | 2026 | 504 | 0.360 |
Why?
|
| Aluminum Compounds | 1 | 2011 | 6 | 0.350 |
Why?
|
| Crime Victims | 2 | 2025 | 59 | 0.350 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2011 | 9 | 0.350 |
Why?
|
| Early Detection of Cancer | 3 | 2026 | 550 | 0.340 |
Why?
|
| Retrospective Studies | 9 | 2024 | 10962 | 0.340 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2011 | 21 | 0.330 |
Why?
|
| Chlorides | 1 | 2011 | 102 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 881 | 0.330 |
Why?
|
| Health Status Disparities | 2 | 2023 | 234 | 0.320 |
Why?
|
| Loose Anagen Hair Syndrome | 1 | 2010 | 5 | 0.320 |
Why?
|
| Beauty Culture | 1 | 2010 | 1 | 0.320 |
Why?
|
| Breast Density | 3 | 2026 | 44 | 0.320 |
Why?
|
| Facial Neoplasms | 2 | 2007 | 26 | 0.320 |
Why?
|
| Alopecia | 1 | 2010 | 36 | 0.310 |
Why?
|
| Breast Neoplasms | 4 | 2026 | 3272 | 0.310 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 95 | 0.310 |
Why?
|
| Hemangioma | 2 | 2007 | 62 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1109 | 0.290 |
Why?
|
| Microphthalmos | 1 | 2008 | 7 | 0.280 |
Why?
|
| Skin Abnormalities | 1 | 2008 | 12 | 0.280 |
Why?
|
| Neonatal Screening | 2 | 2026 | 71 | 0.270 |
Why?
|
| Pachyonychia Congenita | 1 | 2007 | 1 | 0.260 |
Why?
|
| Keratin-6 | 1 | 2007 | 3 | 0.260 |
Why?
|
| Mass Screening | 4 | 2026 | 745 | 0.250 |
Why?
|
| Leukodystrophy, Metachromatic | 1 | 2026 | 1 | 0.250 |
Why?
|
| Breast | 4 | 2026 | 315 | 0.240 |
Why?
|
| Lipoma | 1 | 2006 | 23 | 0.230 |
Why?
|
| Marijuana Use | 1 | 2025 | 13 | 0.230 |
Why?
|
| Anxiety | 2 | 2025 | 370 | 0.230 |
Why?
|
| Depression | 3 | 2025 | 615 | 0.230 |
Why?
|
| Calcinosis | 1 | 2007 | 220 | 0.230 |
Why?
|
| Baths | 1 | 2025 | 10 | 0.220 |
Why?
|
| Chlorhexidine | 1 | 2025 | 6 | 0.220 |
Why?
|
| Skin Care | 1 | 2025 | 7 | 0.220 |
Why?
|
| Mother-Child Relations | 1 | 2025 | 30 | 0.220 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2025 | 26 | 0.220 |
Why?
|
| Skin Aging | 1 | 2025 | 31 | 0.220 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2024 | 19 | 0.220 |
Why?
|
| Maxillofacial Abnormalities | 1 | 2004 | 2 | 0.210 |
Why?
|
| Decision Support Techniques | 1 | 2026 | 194 | 0.210 |
Why?
|
| Tooth Abnormalities | 1 | 2004 | 8 | 0.210 |
Why?
|
| Facial Asymmetry | 1 | 2004 | 13 | 0.210 |
Why?
|
| Tinea Versicolor | 1 | 2024 | 1 | 0.210 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2024 | 3 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2026 | 3618 | 0.210 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 51 | 0.210 |
Why?
|
| Bacteremia | 1 | 2025 | 111 | 0.200 |
Why?
|
| Inflammation | 1 | 2010 | 1120 | 0.200 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2025 | 133 | 0.200 |
Why?
|
| Cross Infection | 1 | 2025 | 155 | 0.200 |
Why?
|
| Breast Feeding | 1 | 2025 | 113 | 0.200 |
Why?
|
| Immune System Diseases | 1 | 2023 | 25 | 0.200 |
Why?
|
| Social Stigma | 1 | 2024 | 95 | 0.190 |
Why?
|
| Clindamycin | 1 | 2023 | 14 | 0.190 |
Why?
|
| Syndrome | 4 | 2008 | 439 | 0.190 |
Why?
|
| Social Media | 1 | 2025 | 118 | 0.190 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2023 | 45 | 0.180 |
Why?
|
| Darier Disease | 1 | 2022 | 5 | 0.180 |
Why?
|
| Hyperpigmentation | 1 | 2022 | 7 | 0.180 |
Why?
|
| Hair Diseases | 1 | 2022 | 9 | 0.180 |
Why?
|
| Problem Behavior | 1 | 2022 | 11 | 0.180 |
Why?
|
| Smallpox Vaccine | 2 | 2014 | 11 | 0.180 |
Why?
|
| Herpesvirus 3, Human | 1 | 2022 | 24 | 0.180 |
Why?
|
| Oligopeptides | 1 | 2023 | 207 | 0.180 |
Why?
|
| Child Behavior Disorders | 1 | 2022 | 76 | 0.180 |
Why?
|
| Spiders | 1 | 2021 | 18 | 0.170 |
Why?
|
| Public Assistance | 1 | 2021 | 10 | 0.170 |
Why?
|
| Erythema | 1 | 2021 | 31 | 0.170 |
Why?
|
| Adult | 8 | 2026 | 29564 | 0.170 |
Why?
|
| Scleroderma, Localized | 1 | 2021 | 9 | 0.170 |
Why?
|
| Necrosis | 1 | 2021 | 212 | 0.170 |
Why?
|
| United States | 8 | 2026 | 8193 | 0.170 |
Why?
|
| Headache Disorders | 1 | 2021 | 7 | 0.170 |
Why?
|
| Body Mass Index | 1 | 2025 | 850 | 0.170 |
Why?
|
| Musculoskeletal Diseases | 1 | 2021 | 38 | 0.160 |
Why?
|
| Face | 1 | 2021 | 117 | 0.160 |
Why?
|
| Hot Temperature | 1 | 2021 | 228 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 403 | 0.160 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2020 | 11 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 369 | 0.160 |
Why?
|
| Diet | 1 | 2023 | 469 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2025 | 580 | 0.150 |
Why?
|
| Hair Color | 1 | 2019 | 8 | 0.150 |
Why?
|
| Career Choice | 1 | 2021 | 161 | 0.150 |
Why?
|
| Melanins | 1 | 2019 | 24 | 0.150 |
Why?
|
| Pregnancy | 2 | 2025 | 3244 | 0.150 |
Why?
|
| Culture | 1 | 2019 | 57 | 0.150 |
Why?
|
| Melanocytes | 1 | 2019 | 62 | 0.150 |
Why?
|
| Primary Prevention | 1 | 2019 | 91 | 0.140 |
Why?
|
| Safety | 1 | 2019 | 138 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2023 | 594 | 0.140 |
Why?
|
| Sex Offenses | 1 | 2018 | 26 | 0.140 |
Why?
|
| Remission, Spontaneous | 1 | 2018 | 45 | 0.140 |
Why?
|
| Comorbidity | 1 | 2022 | 1031 | 0.140 |
Why?
|
| Seizures | 1 | 2021 | 324 | 0.140 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2018 | 7 | 0.140 |
Why?
|
| Firearms | 1 | 2019 | 91 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 634 | 0.130 |
Why?
|
| Young Adult | 3 | 2025 | 7511 | 0.130 |
Why?
|
| Peer Group | 1 | 2018 | 99 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2021 | 2585 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1996 | 0.120 |
Why?
|
| Gestational Age | 1 | 2018 | 341 | 0.120 |
Why?
|
| Wounds, Gunshot | 1 | 2019 | 153 | 0.120 |
Why?
|
| Ectodermal Dysplasia | 1 | 2016 | 2 | 0.120 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2016 | 2 | 0.120 |
Why?
|
| Nails, Malformed | 1 | 2016 | 3 | 0.120 |
Why?
|
| Anodontia | 1 | 2016 | 3 | 0.120 |
Why?
|
| Pigmentation Disorders | 1 | 2016 | 13 | 0.120 |
Why?
|
| Students | 1 | 2018 | 196 | 0.120 |
Why?
|
| Curriculum | 1 | 2021 | 633 | 0.120 |
Why?
|
| Dermoscopy | 1 | 2016 | 8 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 120 | 0.120 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 106 | 0.120 |
Why?
|
| Molecular Docking Simulation | 1 | 2016 | 59 | 0.120 |
Why?
|
| Pruritus | 1 | 2015 | 31 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2018 | 306 | 0.110 |
Why?
|
| Siphonaptera | 1 | 2015 | 8 | 0.110 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 68 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 159 | 0.110 |
Why?
|
| Quality of Life | 1 | 2024 | 1895 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2018 | 370 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 226 | 0.110 |
Why?
|
| Leukemoid Reaction | 1 | 2015 | 5 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 188 | 0.110 |
Why?
|
| Biopsy | 2 | 2026 | 1224 | 0.110 |
Why?
|
| Down Syndrome | 1 | 2015 | 54 | 0.110 |
Why?
|
| Ichthyosis Vulgaris | 1 | 2014 | 1 | 0.110 |
Why?
|
| Arabidopsis Proteins | 1 | 2016 | 144 | 0.110 |
Why?
|
| Intermediate Filament Proteins | 1 | 2014 | 35 | 0.110 |
Why?
|
| Pedigree | 1 | 2016 | 980 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 312 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 601 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2015 | 236 | 0.100 |
Why?
|
| Disease Management | 1 | 2017 | 377 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1535 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1646 | 0.100 |
Why?
|
| Middle Aged | 5 | 2026 | 29442 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 539 | 0.100 |
Why?
|
| Buttocks | 1 | 2013 | 12 | 0.100 |
Why?
|
| Animals | 7 | 2021 | 28902 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2026 | 523 | 0.090 |
Why?
|
| Arm | 1 | 2013 | 100 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2024 | 985 | 0.090 |
Why?
|
| Patch Tests | 1 | 2011 | 4 | 0.090 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2011 | 3 | 0.090 |
Why?
|
| Hepatitis B Vaccines | 1 | 2011 | 17 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 1 | 2011 | 32 | 0.090 |
Why?
|
| Phenotype | 3 | 2020 | 2638 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1815 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 2037 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2012 | 287 | 0.080 |
Why?
|
| Granulation Tissue | 1 | 2010 | 15 | 0.080 |
Why?
|
| Debridement | 1 | 2010 | 64 | 0.080 |
Why?
|
| Scalp | 1 | 2010 | 69 | 0.080 |
Why?
|
| Microscopy | 1 | 2010 | 92 | 0.080 |
Why?
|
| Maus Elberfeld virus | 4 | 1990 | 9 | 0.080 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2010 | 31 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 2555 | 0.080 |
Why?
|
| Mycosis Fungoides | 1 | 2010 | 30 | 0.080 |
Why?
|
| Enterovirus | 4 | 1990 | 16 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2024 | 9713 | 0.070 |
Why?
|
| Kaposi Varicelliform Eruption | 1 | 2008 | 5 | 0.070 |
Why?
|
| Canada | 2 | 2024 | 211 | 0.070 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 56 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2016 | 1717 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 4026 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2010 | 280 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 2013 | 0.060 |
Why?
|
| Ear, External | 1 | 2007 | 24 | 0.060 |
Why?
|
| Dandy-Walker Syndrome | 1 | 2006 | 21 | 0.060 |
Why?
|
| Sternum | 1 | 2006 | 35 | 0.060 |
Why?
|
| Heel | 1 | 2006 | 4 | 0.060 |
Why?
|
| Groin | 1 | 2006 | 11 | 0.060 |
Why?
|
| Aged | 4 | 2025 | 21760 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2026 | 215 | 0.060 |
Why?
|
| Catheter-Related Infections | 1 | 2025 | 26 | 0.050 |
Why?
|
| Radiography | 1 | 2006 | 763 | 0.050 |
Why?
|
| Skull | 1 | 2006 | 280 | 0.050 |
Why?
|
| Linear Models | 1 | 2025 | 424 | 0.050 |
Why?
|
| Protein Binding | 2 | 2020 | 1554 | 0.050 |
Why?
|
| Stereotyping | 1 | 2024 | 21 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2006 | 368 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2023 | 38 | 0.050 |
Why?
|
| Fever | 1 | 2004 | 122 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 7387 | 0.050 |
Why?
|
| Eyebrows | 1 | 2022 | 10 | 0.050 |
Why?
|
| Retinoids | 1 | 2022 | 18 | 0.050 |
Why?
|
| Parenting | 1 | 2022 | 70 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 1 | 2004 | 158 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 327 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 336 | 0.040 |
Why?
|
| Photography | 1 | 2021 | 43 | 0.040 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2020 | 7 | 0.040 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2020 | 16 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2020 | 71 | 0.040 |
Why?
|
| Critical Illness | 1 | 2004 | 436 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 368 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2012 | 67 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2020 | 2005 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 285 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 161 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2023 | 1153 | 0.040 |
Why?
|
| Immunity | 1 | 2020 | 160 | 0.040 |
Why?
|
| Schools | 1 | 2019 | 93 | 0.040 |
Why?
|
| Michigan | 1 | 2018 | 59 | 0.040 |
Why?
|
| Genitalia | 1 | 2018 | 18 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2008 | 238 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2018 | 80 | 0.030 |
Why?
|
| Adolescent Behavior | 1 | 2018 | 118 | 0.030 |
Why?
|
| Anal Canal | 1 | 2018 | 94 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 1133 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 822 | 0.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 195 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 502 | 0.030 |
Why?
|
| WD40 Repeats | 1 | 2016 | 2 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2021 | 829 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2482 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 696 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 301 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 374 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 780 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 2207 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 720 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1383 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2016 | 480 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 470 | 0.020 |
Why?
|
| Binding Sites | 1 | 2016 | 1159 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1327 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1604 | 0.020 |
Why?
|
| Arabidopsis | 1 | 2016 | 331 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3598 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 1990 | 581 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 895 | 0.020 |
Why?
|
| Genes, Viral | 2 | 1990 | 101 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 274 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 310 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 373 | 0.020 |
Why?
|
| Viral Proteins | 2 | 1990 | 252 | 0.020 |
Why?
|
| Capsid | 1 | 1989 | 20 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 3022 | 0.020 |
Why?
|
| Australia | 1 | 2010 | 125 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2572 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1990 | 169 | 0.020 |
Why?
|
| Phthalimides | 1 | 2008 | 7 | 0.020 |
Why?
|
| Isoindoles | 1 | 2008 | 13 | 0.020 |
Why?
|
| Plasma | 1 | 2008 | 49 | 0.020 |
Why?
|
| Organophosphonates | 1 | 2008 | 46 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 4116 | 0.020 |
Why?
|
| Family Health | 1 | 2008 | 156 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2008 | 153 | 0.020 |
Why?
|
| Eye Abnormalities | 1 | 2007 | 41 | 0.020 |
Why?
|
| Mice | 4 | 2016 | 12697 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 6232 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 176 | 0.020 |
Why?
|
| Cytosine | 1 | 2008 | 124 | 0.020 |
Why?
|
| Benzamides | 1 | 2008 | 260 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2008 | 192 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 1013 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 480 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2008 | 338 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2007 | 211 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 1610 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 2080 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1122 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1777 | 0.010 |
Why?
|
| Neurons | 1 | 1990 | 1620 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 1990 | 2896 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2448 | 0.010 |
Why?
|
| Base Sequence | 2 | 1989 | 2222 | 0.010 |
Why?
|
| DNA | 2 | 1990 | 1274 | 0.010 |
Why?
|
| Viral Structural Proteins | 1 | 1990 | 17 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1990 | 146 | 0.000 |
Why?
|
| Restriction Mapping | 1 | 1989 | 119 | 0.000 |
Why?
|
| Capsid Proteins | 1 | 1989 | 26 | 0.000 |
Why?
|
| Enterovirus Infections | 1 | 1989 | 25 | 0.000 |
Why?
|
| Neutralization Tests | 1 | 1989 | 74 | 0.000 |
Why?
|
| Genetic Engineering | 1 | 1990 | 102 | 0.000 |
Why?
|
| Plasmids | 1 | 1989 | 275 | 0.000 |
Why?
|
| Virulence | 1 | 1989 | 280 | 0.000 |
Why?
|
| Epitopes | 1 | 1989 | 258 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1990 | 548 | 0.000 |
Why?
|
| Picornaviridae | 1 | 1988 | 5 | 0.000 |
Why?
|
| Genetic Vectors | 1 | 1989 | 426 | 0.000 |
Why?
|
| Spinal Cord | 1 | 1989 | 244 | 0.000 |
Why?
|
| Recombination, Genetic | 1 | 1990 | 423 | 0.000 |
Why?
|
| Transfection | 1 | 1989 | 883 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1988 | 288 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1988 | 393 | 0.000 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1988 | 412 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1989 | 1416 | 0.000 |
Why?
|